A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Margaret A. Phillips, Julie Lotharius, Kennan Marsh, John White, Anthony Dayan, Karen L. White, Jacqueline W. Njoroge, Farah El Mazouni, Yanbin Lao, Sreekanth Kokkonda, Diana R. Tomchick, Xiaoyi Deng, Trevor Laird, Sangeeta N. Bhatia, Sandra March, Caroline L. Ng, David A. Fidock, Sergio Wittlin, Maria Lafuente-Monasterio, Francisco Javier Gamo BenitoLaura Maria Sanz Alonso, Maria Santos Martinez, Maria Belen Jimenez-Diaz, Santiago Ferrer Bazaga, Iñigo Angulo-Barturen, John N. Haselden, James Louttit, Yi Cui, Arun Sridhar, Anna Marie Zeeman, Clemens Kocken, Robert Sauerwein, Koen Dechering, Vicky M. Avery, Sandra Duffy, Michael Delves, Robert Sinden, Andrea Ruecker, Kristina S. Wickham, Rosemary Rochford, Janet Gahagen, Lalitha Iyer, Ed Riccio, Jon Mirsalis, Ian Bathhurst, Thomas Rueckle, Xavier Ding, Brice Campo, Didier Leroy, M. John Rogers, Pradipsinh K. Rathod, Jeremy N. Burrows, Susan A. Charman

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Malaria is one of the most significant causes of childhood mortality, but disease control efforts are threatened by resistance of the Plasmodium parasite to current therapies. Continued progress in combating malaria requires development of new, easy to administer drug combinations with broad-ranging activity against all manifestations of the disease. DSM265, a triazolopyrimidine-based inhibitor of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH), is the first DHODH inhibitor to reach clinical development for treatment of malaria. We describe studies profiling the biological activity, pharmacological and pharmacokinetic properties, and safety of DSM265, which supported its advancement to human trials. DSM265 is highly selective toward DHODH of the malaria parasite Plasmodium, efficacious against both blood and liver stages of P. falciparum, and active against drugresistant parasite isolates. Favorable pharmacokinetic properties of DSM265 are predicted to provide therapeutic concentrations for more than 8 days after a single oral dose in the range of 200 to 400 mg. DSM265 was well tolerated in repeat-dose and cardiovascular safety studies in mice and dogs, was not mutagenic, and was inactive against panels of human enzymes/receptors. The excellent safety profile, blood- and liver-stage activity, and predicted long half-life in humans position DSM265 as a new potential drug combination partner for either single-dose treatment or once-weekly chemoprevention. DSM265 has advantages over current treatment options that are dosed daily or are inactive against the parasite liver stage.

Original languageEnglish (US)
Article numberaaa6645
JournalScience translational medicine
Volume7
Issue number296
DOIs
StatePublished - Jul 15 2015
Externally publishedYes

Fingerprint

Malaria
Parasites
Drug Combinations
Therapeutics
Liver
Pharmacokinetics
Plasmodium malariae
Blood Safety
Safety
Plasmodium
Chemoprevention
Enzymes
DSM265
dihydroorotate dehydrogenase
Half-Life
Pharmacology
Dogs
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Phillips, M. A., Lotharius, J., Marsh, K., White, J., Dayan, A., White, K. L., ... Charman, S. A. (2015). A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Science translational medicine, 7(296), [aaa6645]. https://doi.org/10.1126/scitranslmed.aaa6645

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. / Phillips, Margaret A.; Lotharius, Julie; Marsh, Kennan; White, John; Dayan, Anthony; White, Karen L.; Njoroge, Jacqueline W.; El Mazouni, Farah; Lao, Yanbin; Kokkonda, Sreekanth; Tomchick, Diana R.; Deng, Xiaoyi; Laird, Trevor; Bhatia, Sangeeta N.; March, Sandra; Ng, Caroline L.; Fidock, David A.; Wittlin, Sergio; Lafuente-Monasterio, Maria; Benito, Francisco Javier Gamo; Alonso, Laura Maria Sanz; Martinez, Maria Santos; Jimenez-Diaz, Maria Belen; Bazaga, Santiago Ferrer; Angulo-Barturen, Iñigo; Haselden, John N.; Louttit, James; Cui, Yi; Sridhar, Arun; Zeeman, Anna Marie; Kocken, Clemens; Sauerwein, Robert; Dechering, Koen; Avery, Vicky M.; Duffy, Sandra; Delves, Michael; Sinden, Robert; Ruecker, Andrea; Wickham, Kristina S.; Rochford, Rosemary; Gahagen, Janet; Iyer, Lalitha; Riccio, Ed; Mirsalis, Jon; Bathhurst, Ian; Rueckle, Thomas; Ding, Xavier; Campo, Brice; Leroy, Didier; Rogers, M. John; Rathod, Pradipsinh K.; Burrows, Jeremy N.; Charman, Susan A.

In: Science translational medicine, Vol. 7, No. 296, aaa6645, 15.07.2015.

Research output: Contribution to journalArticle

Phillips, MA, Lotharius, J, Marsh, K, White, J, Dayan, A, White, KL, Njoroge, JW, El Mazouni, F, Lao, Y, Kokkonda, S, Tomchick, DR, Deng, X, Laird, T, Bhatia, SN, March, S, Ng, CL, Fidock, DA, Wittlin, S, Lafuente-Monasterio, M, Benito, FJG, Alonso, LMS, Martinez, MS, Jimenez-Diaz, MB, Bazaga, SF, Angulo-Barturen, I, Haselden, JN, Louttit, J, Cui, Y, Sridhar, A, Zeeman, AM, Kocken, C, Sauerwein, R, Dechering, K, Avery, VM, Duffy, S, Delves, M, Sinden, R, Ruecker, A, Wickham, KS, Rochford, R, Gahagen, J, Iyer, L, Riccio, E, Mirsalis, J, Bathhurst, I, Rueckle, T, Ding, X, Campo, B, Leroy, D, Rogers, MJ, Rathod, PK, Burrows, JN & Charman, SA 2015, 'A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria', Science translational medicine, vol. 7, no. 296, aaa6645. https://doi.org/10.1126/scitranslmed.aaa6645
Phillips, Margaret A. ; Lotharius, Julie ; Marsh, Kennan ; White, John ; Dayan, Anthony ; White, Karen L. ; Njoroge, Jacqueline W. ; El Mazouni, Farah ; Lao, Yanbin ; Kokkonda, Sreekanth ; Tomchick, Diana R. ; Deng, Xiaoyi ; Laird, Trevor ; Bhatia, Sangeeta N. ; March, Sandra ; Ng, Caroline L. ; Fidock, David A. ; Wittlin, Sergio ; Lafuente-Monasterio, Maria ; Benito, Francisco Javier Gamo ; Alonso, Laura Maria Sanz ; Martinez, Maria Santos ; Jimenez-Diaz, Maria Belen ; Bazaga, Santiago Ferrer ; Angulo-Barturen, Iñigo ; Haselden, John N. ; Louttit, James ; Cui, Yi ; Sridhar, Arun ; Zeeman, Anna Marie ; Kocken, Clemens ; Sauerwein, Robert ; Dechering, Koen ; Avery, Vicky M. ; Duffy, Sandra ; Delves, Michael ; Sinden, Robert ; Ruecker, Andrea ; Wickham, Kristina S. ; Rochford, Rosemary ; Gahagen, Janet ; Iyer, Lalitha ; Riccio, Ed ; Mirsalis, Jon ; Bathhurst, Ian ; Rueckle, Thomas ; Ding, Xavier ; Campo, Brice ; Leroy, Didier ; Rogers, M. John ; Rathod, Pradipsinh K. ; Burrows, Jeremy N. ; Charman, Susan A. / A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. In: Science translational medicine. 2015 ; Vol. 7, No. 296.
@article{8c5f3a5d6e2f46629667c71b9140d281,
title = "A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria",
abstract = "Malaria is one of the most significant causes of childhood mortality, but disease control efforts are threatened by resistance of the Plasmodium parasite to current therapies. Continued progress in combating malaria requires development of new, easy to administer drug combinations with broad-ranging activity against all manifestations of the disease. DSM265, a triazolopyrimidine-based inhibitor of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH), is the first DHODH inhibitor to reach clinical development for treatment of malaria. We describe studies profiling the biological activity, pharmacological and pharmacokinetic properties, and safety of DSM265, which supported its advancement to human trials. DSM265 is highly selective toward DHODH of the malaria parasite Plasmodium, efficacious against both blood and liver stages of P. falciparum, and active against drugresistant parasite isolates. Favorable pharmacokinetic properties of DSM265 are predicted to provide therapeutic concentrations for more than 8 days after a single oral dose in the range of 200 to 400 mg. DSM265 was well tolerated in repeat-dose and cardiovascular safety studies in mice and dogs, was not mutagenic, and was inactive against panels of human enzymes/receptors. The excellent safety profile, blood- and liver-stage activity, and predicted long half-life in humans position DSM265 as a new potential drug combination partner for either single-dose treatment or once-weekly chemoprevention. DSM265 has advantages over current treatment options that are dosed daily or are inactive against the parasite liver stage.",
author = "Phillips, {Margaret A.} and Julie Lotharius and Kennan Marsh and John White and Anthony Dayan and White, {Karen L.} and Njoroge, {Jacqueline W.} and {El Mazouni}, Farah and Yanbin Lao and Sreekanth Kokkonda and Tomchick, {Diana R.} and Xiaoyi Deng and Trevor Laird and Bhatia, {Sangeeta N.} and Sandra March and Ng, {Caroline L.} and Fidock, {David A.} and Sergio Wittlin and Maria Lafuente-Monasterio and Benito, {Francisco Javier Gamo} and Alonso, {Laura Maria Sanz} and Martinez, {Maria Santos} and Jimenez-Diaz, {Maria Belen} and Bazaga, {Santiago Ferrer} and I{\~n}igo Angulo-Barturen and Haselden, {John N.} and James Louttit and Yi Cui and Arun Sridhar and Zeeman, {Anna Marie} and Clemens Kocken and Robert Sauerwein and Koen Dechering and Avery, {Vicky M.} and Sandra Duffy and Michael Delves and Robert Sinden and Andrea Ruecker and Wickham, {Kristina S.} and Rosemary Rochford and Janet Gahagen and Lalitha Iyer and Ed Riccio and Jon Mirsalis and Ian Bathhurst and Thomas Rueckle and Xavier Ding and Brice Campo and Didier Leroy and Rogers, {M. John} and Rathod, {Pradipsinh K.} and Burrows, {Jeremy N.} and Charman, {Susan A.}",
year = "2015",
month = "7",
day = "15",
doi = "10.1126/scitranslmed.aaa6645",
language = "English (US)",
volume = "7",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "296",

}

TY - JOUR

T1 - A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

AU - Phillips, Margaret A.

AU - Lotharius, Julie

AU - Marsh, Kennan

AU - White, John

AU - Dayan, Anthony

AU - White, Karen L.

AU - Njoroge, Jacqueline W.

AU - El Mazouni, Farah

AU - Lao, Yanbin

AU - Kokkonda, Sreekanth

AU - Tomchick, Diana R.

AU - Deng, Xiaoyi

AU - Laird, Trevor

AU - Bhatia, Sangeeta N.

AU - March, Sandra

AU - Ng, Caroline L.

AU - Fidock, David A.

AU - Wittlin, Sergio

AU - Lafuente-Monasterio, Maria

AU - Benito, Francisco Javier Gamo

AU - Alonso, Laura Maria Sanz

AU - Martinez, Maria Santos

AU - Jimenez-Diaz, Maria Belen

AU - Bazaga, Santiago Ferrer

AU - Angulo-Barturen, Iñigo

AU - Haselden, John N.

AU - Louttit, James

AU - Cui, Yi

AU - Sridhar, Arun

AU - Zeeman, Anna Marie

AU - Kocken, Clemens

AU - Sauerwein, Robert

AU - Dechering, Koen

AU - Avery, Vicky M.

AU - Duffy, Sandra

AU - Delves, Michael

AU - Sinden, Robert

AU - Ruecker, Andrea

AU - Wickham, Kristina S.

AU - Rochford, Rosemary

AU - Gahagen, Janet

AU - Iyer, Lalitha

AU - Riccio, Ed

AU - Mirsalis, Jon

AU - Bathhurst, Ian

AU - Rueckle, Thomas

AU - Ding, Xavier

AU - Campo, Brice

AU - Leroy, Didier

AU - Rogers, M. John

AU - Rathod, Pradipsinh K.

AU - Burrows, Jeremy N.

AU - Charman, Susan A.

PY - 2015/7/15

Y1 - 2015/7/15

N2 - Malaria is one of the most significant causes of childhood mortality, but disease control efforts are threatened by resistance of the Plasmodium parasite to current therapies. Continued progress in combating malaria requires development of new, easy to administer drug combinations with broad-ranging activity against all manifestations of the disease. DSM265, a triazolopyrimidine-based inhibitor of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH), is the first DHODH inhibitor to reach clinical development for treatment of malaria. We describe studies profiling the biological activity, pharmacological and pharmacokinetic properties, and safety of DSM265, which supported its advancement to human trials. DSM265 is highly selective toward DHODH of the malaria parasite Plasmodium, efficacious against both blood and liver stages of P. falciparum, and active against drugresistant parasite isolates. Favorable pharmacokinetic properties of DSM265 are predicted to provide therapeutic concentrations for more than 8 days after a single oral dose in the range of 200 to 400 mg. DSM265 was well tolerated in repeat-dose and cardiovascular safety studies in mice and dogs, was not mutagenic, and was inactive against panels of human enzymes/receptors. The excellent safety profile, blood- and liver-stage activity, and predicted long half-life in humans position DSM265 as a new potential drug combination partner for either single-dose treatment or once-weekly chemoprevention. DSM265 has advantages over current treatment options that are dosed daily or are inactive against the parasite liver stage.

AB - Malaria is one of the most significant causes of childhood mortality, but disease control efforts are threatened by resistance of the Plasmodium parasite to current therapies. Continued progress in combating malaria requires development of new, easy to administer drug combinations with broad-ranging activity against all manifestations of the disease. DSM265, a triazolopyrimidine-based inhibitor of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH), is the first DHODH inhibitor to reach clinical development for treatment of malaria. We describe studies profiling the biological activity, pharmacological and pharmacokinetic properties, and safety of DSM265, which supported its advancement to human trials. DSM265 is highly selective toward DHODH of the malaria parasite Plasmodium, efficacious against both blood and liver stages of P. falciparum, and active against drugresistant parasite isolates. Favorable pharmacokinetic properties of DSM265 are predicted to provide therapeutic concentrations for more than 8 days after a single oral dose in the range of 200 to 400 mg. DSM265 was well tolerated in repeat-dose and cardiovascular safety studies in mice and dogs, was not mutagenic, and was inactive against panels of human enzymes/receptors. The excellent safety profile, blood- and liver-stage activity, and predicted long half-life in humans position DSM265 as a new potential drug combination partner for either single-dose treatment or once-weekly chemoprevention. DSM265 has advantages over current treatment options that are dosed daily or are inactive against the parasite liver stage.

UR - http://www.scopus.com/inward/record.url?scp=84937141039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937141039&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aaa6645

DO - 10.1126/scitranslmed.aaa6645

M3 - Article

C2 - 26180101

AN - SCOPUS:84937141039

VL - 7

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 296

M1 - aaa6645

ER -